COMMUNIQUÉS West-GlobeNewswire

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel
04/03/2026
Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Paris, le 4 mars 2026 . Sanofi annonce avoir déposé ce jour un amendement à son Document d’Enregistrement [...]
Compass Health Expands YGo Youth Mobile Crisis Services Across Northwest Washington
04/03/2026
YGo teams in Snohomish, Skagit, and Whatcom counties provide immediate, short-term behavioral health support for youth and families EVERETT, Wash., March 04, 2026 (GLOBE NEWSWIRE) -- Compass Health has expanded its YGo [...]
Koç University Hospital, a Koç Healthcare Institution, is Named Türkiye’s Top Hospital and Ranked Among the Newsweek–Statista World’s Best Hospitals 2026
04/03/2026
ISTANBUL, March 04, 2026 (GLOBE NEWSWIRE) -- Koç University Hospital a leading institution of Koç Healthcare has set the national benchmark for excellence in healthcare. In the recently announced 2026 edition of [...]
Baylor Genetics to Highlight New Data and Product Innovations at 2026 ACMG Annual Clinical Genetics Meeting
04/03/2026
Company’s exhibit theater presentation will highlight multiomic and multimodal innovations in rare disease diagnostics HOUSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics , a leading diagnostic genomics partner [...]
Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
04/03/2026
Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026 . Sanofi announces today the filing of an amendment to its “Document d’ [...]
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
04/03/2026
RAMAT GAN, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a biotechnology company advancing a pipeline of proprietary small-molecule [...]
Elutia Regains Compliance with Nasdaq Listing Requirements
04/03/2026
GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq [...]
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
04/03/2026
– Neurology and Movement Disorder Specialist Adds Deep Clinical and Development Expertise – MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“ [...]
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
04/03/2026
The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial Vancouver, Canada, March 04, 2026 (GLOBE NEWSWIRE) -- [...]
EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026
04/03/2026
EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026 Company to host conference call and webcast on Wednesday, March 25 at 8:30 a.m. EDT AUSTIN, Texas, March 4, 2026 -- EDAP TMS SA ( [...]
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
04/03/2026
Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new, stable crystal form of [...]
Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study
04/03/2026
A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior [...]
BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy
04/03/2026
Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation continues to build [...]
Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility
04/03/2026
Company Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential MACI Commercialization Outside of the U.S. CAMBRIDGE, Mass [...]
Tevogen Announces Reverse Stock Split
04/03/2026
WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of its [...]
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
04/03/2026
SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year [...]
Ardelyx to Participate in Upcoming Investor Conferences
04/03/2026
WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical [...]
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
04/03/2026
PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced [...]
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
04/03/2026
VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]

Pages